Engineered yeast synthesizes increased levels of triacylglycerols, suggesting a cost-effective production method.
Enzymatic synthesis is currently the primary method for preparing 1,3-medium chain- 2-long-chain triacylglycerols (MLM-TAGs), which serve as both a dietary component and clinical nutrient for specific populations. The application of MLM-TAGs is obviously constrained by the high cost of catalysts. Hence, a novel approach was proposed for MLM-TAGs production by engineered yeast. Overexpressing the mutated fas1R1834K increased the production of medium-chain fatty acids (C8-C12) and resulted in an MLM content of 0.41 mol% of the total TAGs. The introduction of RnACSM4 enabled the recombinant to produce MLM-TAGs at a level of 4.2 mol% when supplemented with 0.2 mM sodium laurate. Further deletion of GAT2 and LRO1 increased the content of MLM-TAGs to 6.7 mol%. Iterative optimization involving sodium laurate dosage, culture temperature, and amino acid addition elevated the MLM-TAGs content to 34.4 mol%. Under the optimized conditions, the maximum yield of MLM-TAGs reached 18.5 mg/g DCW, representing a 135-fold improvement over the original strain. This research presents a promising and sustainable alternative for MLM-TAGs production and demonstrates the feasibility of tailoring the acyl composition of intracellular TAGs.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: